Drug General Information
Drug ID
D03GAY
Former ID
DIB013185
Drug Name
H-409/22
Drug Type
Small molecular drug
Indication Cardiovascular disorder [ICD10:I00-I99] Discontinued in Phase 2 [547165]
Company
AstraZeneca plc
Structure
Download
2D MOL

3D MOL

Formula
C28H33N5O3
Canonical SMILES
CC(C1=CC=C(C=C1)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(C2=CC=CC=C<br />2)C3=CC=CC=C3
InChI
1S/C28H33N5O3/c1-19(20-14-16-23(34)17-15-20)32-26(35)24(13-8-18-31-28(29)30)33-27(36)25(21-9-4-2-5-10-21)22-11-6-3-7-12-22/h2-7,9-12,14-17,19,24-25,34H,8,13,18H2,1H3,(H,32,35)(H,33,36)(H4,29,30,31)/t19-,24-/m1/s1
InChIKey
AOUQZUZEYSDMEZ-NTKDMRAZSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Neuropeptide Y receptor type 1 Target Info Antagonist [525884]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
NetPath Pathway FSH Signaling Pathway
Reactome Peptide ligand-binding receptors
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Peptide GPCRs
Endothelin Pathways
GPCR ligand binding
GPCR downstream signaling
References
Ref 547165Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013561)
Ref 525884In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.